Mallinckrodt Receives a Buy from Mizuho SecuritiesBy Austin Angelo
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Mallinckrodt (NYSE: MNK), with a price target of $87. The company’s shares opened today at $55.26, close to its 52-week low of $50.90.
Rivkind Koffler commented:
“We have updated our model ahead of the 3Q:16 Earnings call on Nov 29 and reiterate our Buy rating.”
According to TipRanks.com, Koffler is a top 100 analyst with an average return of 17.0% and a 50.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Mallinckrodt is Strong Buy and the average price target is $91.75, representing a 66.0% upside.
In a report issued on November 16, Leerink Swann also reiterated a Buy rating on the stock with a $92 price target.
Mallinckrodt’s market cap is currently $6.03B and has a P/E ratio of 12.56. The company has a book value ratio of 1.1575.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MNK in relation to earlier this year. Most recently, in May 2016, Hugh O’neill, the Sr. VP & Pres, ARD of MNK bought 1,653 shares for a total of $100,816.
Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the following segments: Specialty Brands, Specialty Generics, and Nuclear Imaging. The Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals. The Specialty Generics segment engages in the production of specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Nuclear Imaging segment manufactures and markets radiopharmaceuticals. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Chesterfield, the United Kingdom.